Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review.

N Wagner, C A Wyler-Lazarevic, S Yerly, C Samer, G Peytavin, K M Posfay-Barbe, A Calmy, J Ambrosioni

Erratum issuedAbstract readReview

In one paragraph

Review in New microbes and new infections, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric patients.Italian journal of pediatrics · 2018
Article

4 · The record

Corrections and comments

Erratum issued
Corrigendum to "Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review" [New Microbes New Infect] 6 (2015) 1-4].2015

5 · Who and what money

Authors and funding

8 authors.

N WagnerDepartment of Paediatrics, Switzerland.

C A Wyler-LazarevicDepartment of Paediatrics, Switzerland.

S YerlyLaboratory of Virology, Department of Genetics and Laboratory Medicine, Switzerland.

C SamerDivision of Clinical Pharmacology and Toxicology, University Hospitals of Geneva, Switzerland.

G PeytavinDepartment of Clinical Pharmaco-Toxicology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

K M Posfay-BarbeDepartment of Paediatrics, Switzerland.

A CalmyDivision of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland.

J AmbrosioniDivision of Infectious Diseases, Department of Medical Specialties, Geneva University, Geneva, Switzerland ; Infectious Diseases Department, Hospital-Clinic-IDIBAPS, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of multidrug-resistant human immunodeficiency virus (MDR HIV) infections in children is particularly challenging due to the lack of experience with new drugs. Dolutegravir, combined with an optimized antiretroviral background therapy, is promising for the treatment of MDR HIV and has been approved recently for adults and adolescents. Data for children are extremely limited. We describe the efficacy, safety and plasmatic levels of a dolutegravir-based, complex active antiretroviral treatment regimen in a severely overweight 11-year-old child infected with an MDR HIV strain.

Indexed as

Childrendolutegravirmultidrug-resistant human immunodeficiency virusrescue therapyT-20

Identifiers

PMID26082840

DOI10.1016/j.nmni.2015.02.003

PMCPMC4430707

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.